Cyclotron operators
Add Ac‑225 and Pb‑212 production to an existing 19–30 MeV cyclotron, or explore other neutron‑produced radionuclides on machines operating at energies as low as 16 MeV.
Discuss a partnershipMore Alphas.
More Places.
More Patients.
EnVoy‑LAB has developed a high‑yield platform for producing actinium‑225 and lead‑212 using fast neutrons generated on existing 19–30 MeV cyclotrons. The platform can also produce a broader range of medically important radionuclides on cyclotrons operating at energies as low as 16 MeV. EnVoy deploys its technology through established production partners with cyclotrons and radiochemical processing facilities. Interested in becoming one of our partners?
The supply challenge
Alpha therapies are advancing faster than isotope supply
Actinium‑225 and lead‑212 are the “active ingredients” in Targeted Alpha Therapy (TAT), one of the most promising advances in cancer care today. It destroys cancer cells with exquisite precision, minimizing damage to surrounding healthy tissue. However, reliable access to these critical radioisotopes remains an important consideration for the more than 45 ongoing human clinical TAT trials that depend on them.
Most production routes rely on rare nuclear reactors, high‑energy accelerators, or long capital projects. EnVoy’s patent‑pending platform uses existing 19–30 MeV standard cyclotrons, already installed around the world, to produce significant quantities of actinium‑225 and lead‑212 in a safe, scalable way. On cyclotrons operating at energies as low as 16 MeV, the same fast‑neutron platform can also support production pathways for a broader portfolio of medically important radionuclides, such as Cu‑64 and Cu‑67. The use of both existing and commercially‑available cyclotrons makes this approach ideally suited for enabling decentralized production and ensuring a safe, reliable supply chain.
One platform produces both isotopes
With our platform, a proton beam strikes our proprietary target and generates fast neutrons. The neutrons then irradiate sealed radium‑226 and produce radium‑225, decaying to Ac‑225, and radium‑224, decaying to Pb‑212.
Ac‑225, Pb‑212, or both can be produced during the same irradiation. Because the protons never strike the radium directly, the process avoids the severe target heating that complicates other proton‑ or photon‑based methods.
See how it works
Expected Yields
Production on Standard Cyclotrons
Cyclotron range19–30 MeV
Ra‑225 production18–260* mCi per week
Pb‑212 production5–255* mCi per day
The stated yields were demonstrated using 22 MeV protons and based on one gram of Ra‑226. Yields at 24–30 MeV are expected to be >30% higher than the ranges provided here. Production at a specific site will depend on beam energy, current, target configuration, operating schedule, frequency of chemical separation, and radium quantity. These ranges describe Ac‑225 and Pb‑212 production on 19–30 MeV cyclotrons and do not represent the energy requirements or expected yields of other radionuclides supported by the platform.
Distributed production reduces time and supply risk
Because we are deploying our platform through existing partners and facilities, this model can add production in months rather than waiting years for a new facility. It also allows production in locations closer to radiopharmaceutical manufacturing and patients, which matters for short‑lived radioisotopes such as Pb‑212, with its 10.6‑hour half‑life. We enable a tremendous paradigm shift for the industry, similar to the decentralized development of PET tracers.
Built for partnership
Isotope producers and CDMOs
Increase Ac‑225 and Pb‑212 capacity and explore additional neutron‑produced radioisotopes using facilities, people, and systems already in place.
Radiopharmaceutical developers
Assure supply by activating and working with reliable, resilient, and geographically diverse production partners.
We don’t make drugs. We make alpha therapies possible.
EnVoy combines Berkeley‑developed nuclear science, specialized target engineering, and direct inventor support to help partners establish reliable Ac‑225 and Pb‑212 production.